Co-Chairman
George Wilding is currently Director of the Paul P. Carbone Comprehensive Cancer Center and Anderson Professor of Clinical Oncology of the Department of Medicine of UW-Madison and an internationally recognized leader and clinician in the fields of Oxidative Stress and prostate cancer prevention and therapy. He is a member of the Editorial Board of the Journal “The Prostate” and is recognized as a world expert in Androgen-induced Oxidative Stress.
Dr. Wilding is the principal inventor of the CPC-100 prostate cancer therapeutic drug and a major collaborator with Hirak Basu in the invention of CPC-200. As the current University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Director of Clinical Research, he oversees peer-reviewed cancer research funding at UWCCC. The UWCCC’s greatest strength is its involvement in groundbreaking clinical trials and research studies conducted to answer specific scientific questions about new ways to diagnose and treat cancer. They have over 30 years experience in conducting cancer clinical trials and in 1979, the UWCCC started conducting Phase I clinical trials, the first step in evaluating new treatments. At that time, the UWCCC was among only 6 institutions in the country to be funded by the National Cancer Institute (NCI) to conduct such studies. Today, 18 institutions, including the UWCCC are NCI-funded Phase I facilities. About 250 clinical trials are available for patient enrollment at the Cancer Center with more than 700 patients participating each year.
Dr. Wilding graduated from the University of Massachusetts Medical School where he also completed his training in Internal Medicine. He underwent training in Medical Oncology at the National Cancer Institute. He joined the UW School of Medicine and Public Health faculty to focus on the development of new cancer therapies, particularly aimed at progressive and advanced prostate cancer.
He is currently the principal investigator on grants funded by the National Cancer Institute, Department of Defense, and private foundations, such as Prostate Cancer Foundation. His research teams are conducting studies in the laboratory and in the clinics aimed at developing and testing new cancer treatments. New therapies targeting angiogenesis, cell signaling and differentiation are now being tested. All of these areas of investigation are tightly linked to laboratory research groups to provide a strong basic science foundation for translational research.
